Preclinical efficacy and safety models for mAbs: The challenge of developing effective model systems

IDrugs

Volumn 12, Issue 2, 2009, Pages 103-108

  Dixit, R ^a   Coats, S ^a  

^a MEDIMMUNE   (United States)

Author keywords

mAb; Preclinical efficacy model; Preclinical safety model; Transgenic mice

Indexed keywords

BLINATUMOMAB; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CROSS REACTION; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL ANIMAL; LIGAND BINDING; NONHUMAN; PHARMACODYNAMICS; PRIMATE; PROTEIN TARGETING; REVIEW; RODENT; STANDARD; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, ANIMAL; MODELS, BIOLOGICAL; SPECIES SPECIFICITY; TOXICITY TESTS;

EID: 60049093113     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Lonberg N: Human antibodies from transgenic animals. Nat Biotechnol (2005) 23(9):1117-1125.
2. Gerber HP, Wu X, Yu L, Wisemann C, Liang KH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng G et al: Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA (2007) 104(9):3478-3483.
3. Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A: Side effects of approved molecular targeted therapies in solid cancers. The Oncologist (2007) 12(12):1443-1455.
4. Zbinden G: Safety evaluation of biotechnology products. Drug Safety (1990) 10(1):58-64.
5. Dixit R, Boelsterli U: Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Disc Today (2007) 12(7-8):336-342.
6. Green MD, Hartsbough M: The role of pharmacokinetics and pharmacodynamics in selecting a relevant species. In: Preclinical safety evaluation of Biopharmaceuticals. Cavagnaro J (Ed), John Wiley and Sons Inc, Hoboken, NJ, USA (2008).
7. Cavagnaro J (Ed): Preclinical safety evaluation of monoclonal antibodies. John Wiley and Sons Inc, Hoboken, NJ, USA (2008).
8. Clarke J, Leach W, Pippig S, Joshi A, Wu B, House R, Beyer J: Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a mAb. Regul Toxicol Pharmacol (2004) 40(3):219-226.
9. Baeuerle PA, Reinhardt C, Kufer P: BITE: A new class of antibodies that recruit T-cells. Drugs Future (2008) 33(2):137-147.
10. Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandt C, Lippold S, Cobb K, Bransky K, Leo E et al: T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother (2006) 55(5):503-514.